Hospira to Host Biosimilars Investor Education Event |
(Archive News Story - Products mentioned in this Archive News Story may or may not be available from the manufacturer.)
Hospira Worldwide, Inc.
275 N. Field Dr.
Lake Forest, IL, 60045
USA
Press release date: August 12, 2010
LAKE FOREST, Ill., Aug. 12 - Hospira, Inc. (NYSE: HSP), a leading global specialty pharmaceutical and medication delivery company, today announced that it will host a biosimilars investor education forum on Thursday, Aug. 19, 2010. The event, which will feature presentations by various members of the company's R&D and Specialty Pharmaceuticals organizations, will highlight biosimilars in general, as opposed to focusing on the company's biosimilar program.
A streaming audio webcast of the event, which will include the slides presented during the event, will be available on the Investor Relations section of Hospira's Web site at www.hospirainvestor.com. The presentations are expected to begin at approximately 8 a.m. Central time and conclude at approximately 12 p.m. They will be available to all interested parties through a live audio webcast accessible via the investor relations section of Hospira's Web site at www.hospirainvestor.com. Listeners should log on approximately 10 minutes in advance to ensure proper setup for accessing the audio webcast. A replay of the webcast will be available on the Hospira Web site approximately 24 hours after the conclusion of the event.
About Hospira
Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 13,500 employees. Learn more at www.hospira.com.
Source: Hospira, Inc.
Contact:
Media,
Stacey Eisen,
+1-224-212-2276,
or Financial Community,
Karen M. King,
+1-224-212-2711,
or Ruth E. Venning,
+1-224-212-2774,
all of Hospira, Inc.
Web Site: http://www.hospira.com/
|
User comments about this story
Biosimilars in India
My colleagues and I have authored what we believe is India’s first ever complete mapping of the Biosimilars opportunity in India. The report is nowbeing made available to the general public.
Various issues have been dealt with, such as:
- Patent expirations
- Regulatory frameworks
- Infrastructure Requirements
- Etc.
If anyone is interested in this report, please contact me at (infoalcpl AT gmail DOT com), and I would send you the brochure and other details.
By Ashritha on Oct 7, 2010 08:28
Reply to this comment
|
|
|
|
|
|
|
|
|
| 
